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Cancer detection in its early stages is imperative for effective cancer treatment and
patient survival. In recent years, biomedical imaging techniques, such as magnetic
resonance imaging, computed tomography and ultrasound have been greatly developed
and have served pivotal roles in clinical cancer management. Molecular imaging (MI) is
a non-invasive imaging technique that monitors biological processes at the cellular and
sub-cellular levels. To achieve these goals, MI uses targeted imaging agents that can bind
targets of interest with high specificity and report on associated abnormalities, a task that
cannot be performed by conventional imaging techniques. In this respect, MI holds great
promise as a potential therapeutic tool for the early diagnosis of cancer. Nevertheless,
the clinical applications of targeted imaging agents are limited due to their inability to
overcome biological barriers inside the body. The use of nanoparticles has made it possible
to overcome these limitations. Hence, nanoparticles have been the subject of a great deal
of recent studies. Therefore, developing nanoparticle-based imaging agents that can target
tumors via active or passive targeting mechanisms is desirable. This review focuses on the
applications of various functionalized nanoparticle-based imaging agents used in MI for the
early detection of cancer.
Keywords: nanoparticle, molecular imaging, cancer early diagnostics, iron oxide nanoparticles, gadolinium,
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INTRODUCTION
Cancer is one of the world’s most debilitating diseases, and its
mortality rates continue to increase. More than 16 million new
cancer cases are registered every year, and the medical expenses
for overall clinical cancer treatment are practically unaffordable
for most patients (Jemal et al., 2011; Morgan et al., 2011; Siegel
et al., 2014). These increases in cancer mortality rates are due to
a lack of early detection and subsequent treatment. Biomedical
imaging techniques, such as magnetic resonance imaging (MRI),
optical imaging (OI), X-ray computed tomography (CT) and
ultrasound play crucial roles in clinical oncology (Weissleder,
2002; Juweid and Cheson, 2006; Fass, 2008) (Table 1). These
imaging methods can provide essential information regarding
tumor location, size, and distribution at high spatial resolution.
The information obtained from these imaging modalities greatly
assists clinicians in treatment strategy selection, which is benefi-
cial for patients. Unfortunately, conventional biomedical imaging
techniques detect cancerous tumors when they are more than a
centimeter in diameter; at this stage, the lesion already consists
of more than 109 cells. Here, molecular imaging (MI) is likely
to serve a pivotal role because it enables visualization of impor-
tant biological processes that are associated with the early stages
of carcinogenesis in a detailed and specific manner using tar-
geted imaging agents. MI is more sophisticated than conventional
bioimaging because the contrast agents consist of tumor-specific
ligands, such as antibodies or peptides. These agents may also
be small molecules or signaling moieties, such as fluorophores
or radionuclides, or paramagnetic metal chelates. A typical con-
trast agent is expected to accumulate selectively at a desired site
and interact physically or chemically with a target, thereby alter-
ing the imaging contrast. Hence, MI serves an integral role in
the early detection of cancer and in drug discovery and develop-
ment (Rudin and Weissleder, 2003; Jaffer and Weissleder, 2005;
Weissleder, 2006; Willmann et al., 2008; Pysz et al., 2010; Hussain
and Nguyen, 2014).
In general, targeted organic fluorophores and radioisotopes
are commonly used as contrast agents in MI (Ballou et al., 1995;
Becker et al., 2001; Massoud and Gambhir, 2003; Pham et al.,
2004; Schnell et al., 2009). Contrast agents must possess long cir-
culation times and the ability to reach the desired target site at an
adequate concentration, which is highly essential for their suc-
cessful detection in vivo. Unfortunately, clinical applications of
contrast agents are severely limited due to their short half-lives,
their ability to elicit an immune response and the difficulty that
they experience with crossing biological membranes. As a result,
only a few imaging agents (For example, Feridex®, Magnevist®,
Gadavist®, AK Fluor®, Fluorescite®, IC-Green®, etc.) approved
by Food and Drug Administration (FDA, USA) are available for
clinical use.
In recent years, nanoparticles have gained significant attention
as contrast agents for the early detection of cancer (Figure 1).
Using nanoparticles, it is possible to (1) achieve high specificity
toward a target, thereby eliminating the danger of side effects;
(2) deliver a large payload amount in a single dose and (3)
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FIGURE 1 | Targeted nanoparticles for MI.
simultaneously deliver both imaging agents and therapeutics.
Carefully designed nanoparticle-based contrast agents (NCAs)
could overcome biological barriers and reach tumors through
either active or passive targeting mechanisms (LaVan et al., 2003;
Ferrari, 2005; Couvreur and Vauthier, 2006; Peer et al., 2007)
(Figure 2). In passive targeting, a distinguishing feature of a
tumor enables an NCA to accumulate and be retained in the
tumor via the enhanced permeation and retention (EPR) effect.
In contrast, active targeting involves the conjugation of targeting
ligands to the surface of the NCA, enabling the NCA to enter the
cancer cell via receptor-mediated endocytosis (Saravanakumar
et al., 2009; Choi et al., 2010; McCarthy et al., 2010). The aim
of this review is to highlight various NCAs used for early cancer
detection with MI.
MRI
MRI uses the nuclear magnetic resonance signals of hydrogen
atoms in water to generate images. After a brief radiofrequency
pulse, the rate at which protons relax back to their equilibrium
state, dependent on their physiochemical environment, gives rise
to an MRI signal. MRI holds great potential as a clinical imag-
ing and diagnostic tool due to its excellent soft tissue contrast,
high spatial resolution, and ability to deeply penetrate tissues
(Stark and Bradley, 1999; Jacobs and Cherry, 2001; Sosnovik and
Weissleder, 2007). The most commonly used contrast agents (T1
and T2) for clinical cancer diagnosis are gadolinium chelates and
superparamagnetic iron oxide nanoparticles (SPIOs) (McCarthy
and Weissleder, 2008; Islam and Josephson, 2009; Lin et al., 2009;
Cheng et al., 2013; Zhou and Lu, 2013). Bare SPIOs are used in the
clinic to image liver tumors and metastases with sharp contrast,
providing clear distinction between normal and cancerous tissues.
FIGURE 2 | Illustration of mechanism of tumor targeting (A) active
targeting and (B) passive targeting.
This diagnostic ability arises from the fact that SPIOs are read-
ily taken up by reticuloendothelial cells (Kupffer cells), which are
absent from or present in lower concentrations in tumors (Saini
et al., 1987; Lin et al., 2009). SPIOs with diameters of 30 nm are
known to accumulate in lymph nodes by interstitial–lymphatic
fluid transport and can be consequently used to detect lymph
nodemetastases (Anzai et al., 2003). In addition, ultrasmall SPIOs
(USPIOs) have been investigated as contrast agents for improv-
ing the delineation of brain tumors on MR images (Enochs et al.,
1999; Neuwelt et al., 2004).
IRON OXIDE NANOPARTICLES
To improve tumor detection and localization, SPIOs are chemi-
cally modified with ligand molecules that target specific upreg-
ulated receptors or proteins and serve as MI probes. Yang et al.
developed functionalized iron oxide nanoparticles (IOs) to tar-
get urokinase-type plasminogen activator receptor (uPAR). uPAR
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is well known to be upregulated in a variety of tumor cells
and tumor-associated endothelial cells, such as fibroblasts and
macrophages (Han et al., 2005). High uPAR expression is closely
associated with metastasis and tumor invasiveness; hence, uPAR
is an excellent target for imaging breast cancer cells. In this study
by Yang et al., IOs were coated with a carboxylic acid-bearing
amphiphilic polymer. The large number of carboxylic groups on
the surface allowed covalent modification with poly(ethylene gly-
col) (PEG) and uPA bearing Cy5.5. Confocal microscopy experi-
ments demonstrated effective uptake of the targeted nanoparticles
by uPA receptors, which were overexpressed on mouse mam-
mary tumor 4T1 cells, whereas human breast cancer T47D cells
that lacked uPA receptors did not uptake the nanoparticles.
Biodistribution studies in 4T1 tumor-bearing mice demonstrated
significant accumulation of the nanoagent in the tumors and
showed increased fluorescence signal intensity for up to 48 h.
Similar tumor-targeting properties of these nanoagents were also
observed using MR imaging in a mouse model (Yang et al., 2008).
In another study, Yang et al. used the amino-terminal fragment
(ATF) of the high affinity receptor binding domain of uPA-
conjugated IOs to target uPAR. The results of this study showed
that ATF-conjugated IO specifically bound to uPAR andwas taken
up by the cells. In vivo systemic delivery of ATF-IO nanoparticles
showed selective accumulation in orthotopic pancreatic tumors,
as demonstrated by both OI/MR imaging. In vivo OI clearly
showed strong near infrared signals in the pancreatic tumors;
however, no signal was detected in the liver or spleen of the
tumor-bearing mice that received Cy5.5-ATF-IO nanoparticles.
Additionally, the targeted nanoparticles exhibited high sensitivity
and were able to detect tumors as small as 0.5–1mm3 in animal
tumormodels usingMRI. The authors suggested that the targeted
nanoparticles used in this study have the potential for early detec-
tion of pancreatic cancer lesions by MRI and for intraoperative
delineation of tumor margins and peritoneal metastases by OI
(Yang et al., 2009a).
Chen et al. developed herceptin (HP)-conjugated cross-linked
iron oxide nanoparticles (CLIOs) for breast cancer imaging.
HP is a monoclonal antibody that has the ability to bind
HER-2/neu receptors, which are overexpressed in breast cancer
cells (Tran et al., 2007). Primary amine-functionalized CLIOs
were prepared by cross-linking dextran-coated SPIOs with 2,2′-
(ethylenedioxy)bisethylamine, followed by chemical conjugation
with HP. In vitro studies demonstrated efficient uptake of tar-
geted CLIOs in HER-2/neu receptor-overexpressing cancer cells
(SKBr3, MDA-MB-231, and MCF-7); uptake was not observed
in KB cells that lacked HER-2/neu receptors. From in vivo MRI
studies, the results showed that when administered intravenously
in mice bearing SKBr3 and KB tumors, targeted CLIOs selectively
accumulated in the SKBr3 tumors but not in the KB tumors, as
confirmed by the darkening of the tumors in T2-weighted images
(Chen et al., 2009). Li et al. developed octreotide peptide (OP)-
modified USPIOs to target somatostatin receptors (SSR) in breast
cancer cells. Somatostatin (ST), a polypeptide known as soma-
totropin release inhibiting factor (SRIF), exhibits an affinity for
the receptors overexpressed in neuroendocrine tumors and on
cells of the immune system. OP is an analog of ST that has the
ability to bind several SSR subtypes. To prepare SSR-targeted
contrast agents, one end of dicarboxylated PEG was attached to
USPIOs, and the other end was conjugated to OPs. In vitro MR
imaging results revealed that the targeted nanoparticles displayed
significantly lower T2 signal values, suggesting efficient uptake
by breast carcinoma MCF-7 cells compared to non-targeted
nanoparticles. For in vivo MR imaging studies, both targeted and
non-targeted nanoparticles were administered to MCF-7 tumor-
bearing mice. The results showed that the targeted nanoparticles
accumulated in the tumor, which was confirmed by the observed
signal decrease in T2-weighted images. In addition, non-targeted
nanoparticles also exhibited a small decrease in signal; this might
be due to random accumulation in the tumor by the EPR effect (Li
et al., 2009). Luteinizing hormone-releasing hormone (LHRH) is
known to bind LHRH receptors that are overexpressed on breast
cancer cell membranes (Leuschner et al., 2005). Hence, LHRH is
a suitable breast tumor-targeting molecule. Meng et al. developed
LHRH receptor-targeted SPIOs to image breast tumors. In vitro
and in vivo studies in breast cancer cells demonstrated the use
of targeted nanoparticles as tumor-specific T2 contrast agents in
relevant models. The cell uptake behavior of targeted SPIOs was
much greater than that of bare SPIOs. The increased uptake and
intracellular accumulation of targeted SPIOs provided enhanced
T2 contrast with improved spatial resolution. The improved tar-
geting by this nanoagent may also be used for cancer therapy via
loading the nanoparticles with therapeutic drugs (Meng et al.,
2009).
Kelly et al. developed a new peptide (IPL) to image prostate
cancer. IPL has the ability to bind a type II transmem-
brane serine protease called hepsin (HPN), which is uniquely
expressed in prostate cancer cells. In this study, IPL was
conjugated to a bimodal nanoparticle that bore an optically
detectable fluorophore attached to IOs. In a mouse xenograft
model, HPN-targeted nanoparticles exhibited high specificity for
HPN-overexpressing LNCaP xenografts compared to non-HPN-
expressing xenografts. The authors proposed that HPN-targeted
nanoparticles could be used for the early detection of prostate
cancer (Kelly et al., 2008). Kresse et al. developed transferrin
(Tf)-conjugated USPIOs for targeting malignant tumors. Tf is
an iron-transporting serum glycoprotein that has the ability to
bind specific receptors that are overexpressed in various cancer
cells (Hopkins and Trowbridge, 1983). In vivo MR imaging stud-
ies in SMT/2A tumor-bearing rats showed that targeted USPIOs
exhibited substantial signal reduction (40%) in T2-weighted MR
images. In addition, control experiments using bare USPIOs
or non-specific human serum albumin-conjugated USPIOs also
accumulated in the tumors with a 10% change in the MR sig-
nal intensity, most likely due to non-specific accumulation in the
tumors (Kresse et al., 1998). Choi et al. used folic acid (FA)-
conjugatedmagneto-fluorescent nanoparticles as a targeted imag-
ing agent for cancer detection. FA is essential for cell proliferation
and for the maintenance of new cells during rapid cell division.
Folate receptors are frequently upregulated in various cancer cells,
enabling cancer cells to access vitamins necessary for their sur-
vival (Antony, 1996; Lu and Low, 2002). Hence, folate-targeted
imaging probes are useful for the detection of cancer cells that
overexpress folate receptors. In vitro confocal observation showed
a strong fluorescence signal in folate receptor-overexpressing KB
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cells incubated with the targeted nanoagent, whereas no fluo-
rescence signals were detected in cells (human lung carcinoma)
lacking folate receptors. An in vivo MR imaging study in a mouse
KB tumor xenograft model showed that the targeted nanoa-
gent exhibited an average intensity decrease of 38% from pre-
to post-contrast images of the tumor, which was approximately
three times the intensity decrease observed in a non-tumor-
bearingmouse. These targeted nanoparticles are highly specific
and can be used as targeted delivery systems for tumor diagnosis
and therapy (Choi et al., 2004).
For targeting brain tumors, Meng et al. developed SPIOFCs,
a dual imaging nanoparticle consisted of chlorotoxin (CTX) and
fluorescein isothiocyanate (FITC) conjugated to SPIOs. CTX, a
small peptide found in the deathstalker scorpion (Leiurus quin-
questriatus), is a highly specific marker for glioma cells and has
been used for brain tumor targeting in animal models (Soroceanu
et al., 1998). In vitro studies demonstrated that prepared SPIOFCs
did not induce any toxicity and showed increased cellular uptake
in human U251-MG and rat C6 glioma cells when evaluated
by MR imaging and inductively coupled plasma emission spec-
troscopy (ICPMS). Glioma cells were found to be insensitive
to bare nanoparticles without CTX and showed no significant
uptake; these findings suggested that the presence of CTX was
essential for specific and efficient targeting of glioma cells (Meng
et al., 2007). Another study by Sun et al. used CTX-conjugated
PEGylated iron oxide nanoparticles (CPIs) as an MI probe to
detect gliomas. In general, the presence of PEG in nanoparticles
offers stealth properties and allows the conjugation of various
molecules, such as diagnostic, targeting, and therapeutic agents.
In vitro MR imaging showed increased cellular uptake of CPI
nanoparticles in 9L gliosarcoma cells compared to non-targeted
nanoparticles. In athymic (nu/nu) mice bearing 9L gliosarcoma
xenograft tumors, CPIs gradually accumulated in the tumors over
time as expected, and small amounts of non-targeted nanoparti-
cles also reached the tumors through non-specific mechanisms.
The contrast enhancement degree was quantified by measur-
ing the R2 relaxation rates (Sun et al., 2008). For the specific
identification of apoptotic cells, Schellenberger et al. chemically
conjugated CLIOs to annexin-V, a protein that binds to extra-
cellular phosphatidylserine, an early marker of apoptosis (Martin
et al., 1995). In this study, Jurkat T lymphoma cancer cells were
used, it is well known that insufficient apoptosis is one of the
characteristic features of cancer cells. For specific identification,
apoptosis was induced in Jukart cells using camptothecin, an
anticancer drug. From in vitroMRI studies, it was found that tar-
geted CLIOs identified camptothecin-induced apoptosis of Jurkat
T cells, which was confirmed by the significant signal decrease rel-
ative to untreated cells; in contrast, bare CLIOs failed to induce
significant changes in apoptotic cells. These results suggest that
the targeted CLIOs used in this study can serve as an MRI probe
for imaging apoptosis in vivo (Schellenberger et al., 2002).
Clearance of IOs
In general, intravenously administered IOs are cleared from blood
circulation by reticulo endothelial system (Corot et al., 2006).
However, the various properties such as shape, size, and sur-
face characteristics largely determine the pharmacokinetics and
clearance. For instance, IOs with larger size are eliminated faster
than smaller-sized NPs. Jain et al. investigated the biodistribution,
clearance, and biocompatibility of IOs sequentially coated with
oleic acid and pluronic (Pluronic-OA-IO). Usually, IO formula-
tions use dextran or starch coating as a stabilizing agent to form a
water-dispersible system. In this study, pluronic or PEGwere used
as coating materials, which are known to prevent opsonization. In
vivo biodistribution studies of Pluronic-OA-IO (193 nm) showed
about 55% of the injected iron accumulated in the liver. A grad-
ual increase in the serum iron level was observed for 1 week,
which indicated that clearance of nanoparticles require more than
3 weeks (Jain et al., 2008).
Lewis et al. studied the biodistribution of Ferumoxtron-10, a
USPIO (30 nm in diameter) coated with low molecular weight
dextran. Ferumoxtran-10 demonstrated slow clearance of iron
and was eliminated (89%) in the urine in 7 weeks. Iron con-
tained in Ferumoxtron-10 was absorbed into the body’s iron store
and gradually into hemoglobin. Like endogeneous iron, it was
eliminated slowly (16–21%) after 84 days through hepatobiliary
mechanism (Bourrinet et al., 2006).
GADOLINIUM-BASED NANOPARTICLES
Paramagnetic gadolinium (Gd) complexes are the most widely
used T1 contrast agents for clinical applications of MRI (Caravan
et al., 1999; Lee et al., 2014). In recent years, many researchers
have investigated the use of several targeted Gd complexes for the
early detection of cancer (Damadian, 1971; Zhou and Lu, 2013;
Hussain and Nguyen, 2014). The use of Gd complexes as posi-
tive contrast agents in T1-weighed MRI sequences is limited by
their sensitivity. Hence, Gd complexes are usually encapsulated
in nanocarriers or are chemically conjugated to synthetic poly-
mers, such as dendrimers, to amplify their sensitivity (Kobayashi
and Brechbiel, 2003, 2005; Luo et al., 2011). For targeting pur-
poses, Gd complexes are covalently conjugated to targeted lig-
ands, which dock and respond to specific receptors that are
overexpressed in cancer cells.
Dendrimers are self-assembled polymer constructs with tun-
able surface and are widely used as carriers for Gd-based con-
trast agents. Xu et al. developed a bimodal second-generation
(G2) dendrimer nanoparticle that consisted of covalently con-
jugated Gd-1B4M- diethylenetriaminepentaacetate (DTPA) and
optically detectable rhodamine green for targeting ovarian can-
cer (Figure 3). The nanoparticles achieved success in reaching
tumor tissues and delivered significant amounts of imaging pay-
loads in an ovarian tumor-bearing mouse xenograft model to
produce detectable changes in the tumors by optical andMRI (Xu
et al., 2007). Regino et al. evaluated the use of the dendrimer-
based contrast agent Gd-G8 as a dual MRI and CT contrast
agent for precisely monitoring convection-enhanced delivery to
the brain. From in vitro studies, CT-based attenuation values of
the Gd-based agent were∼1.6 times greater than those of iopami-
dol (an iodine-based agent); moreover, the attenuation of the
Gd-G8 dendrimer was similar to that of Gd-DTPA. In vivo stud-
ies demonstrated that detectable signal enhancement could be
observed by CT and MRI with an optimal dose of Gd-G8 over
a range of 23–78mM; however, for the adequate delineation of
the injection site on MRI and CT, a concentration of at least
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FIGURE 3 | (A) Structure of a PAMAM dendrimer possessing a disulfide
cystamine core; (B) T1-weighed MR image obtained prior to contrast agent
injection (t = 0) reveals an area of tumor growth below the liver, stomach and
spleen in the left abdomen (green arrow) and adjacent to the gastrointestinal
tract in the lower right abdomen (orange arrow) and (C) T1-weighted MR
image obtained 6.5 h after intra-peritoneal injection of the dual contrast
agent (green and orange arrows indicate signal enhancement on the tumor
surface) (Xu et al., 2007), © 2007, American Chemical Society.
47mM was required, and the distribution volume (Vd) was esti-
mated with greater sensitivity by MRI than by CT (Regino et al.,
2008).
Swanson et al. prepared a target-specific multifunctional
nanoparticle, Gd(III)-DOTA-G5-FA that consisted of Gd-
complexed, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA) and FA conjugated to a G5 poly (amidoamine)
(PAMAM) dendrimer. In vivo studies were performed in a
NODCB-17 SCID mouse xenograft model with KB tumors.
When administered subcutaneously, the Gd(III)-DOTA-G5-FA
dendrimer nanoparticles specifically reached the tumors and gen-
erated statistically significant MRI signal enhancement compared
to non-targeted counterparts (Gd(III)-DOTA-G5). Sustained
signal enhancements in the tumors were observed even at 48 h
post-injection, suggesting the effective tumor-targeting ability
of Gd(III)-DOTA-G5-FA (Swanson et al., 2008). Huang et al.
prepared multifunctional dendrigraft poly-L-lysines (D2 and D3)
composed of covalently attached CTX and Gd-DTPA. The OI
results showed that CTX dendrimer conjugates were readily taken
up by C6 glioma and liver tumor cell lines but were not taken up
by normal cell lines. Intracranially administered CTX dendrimer
conjugates in C6 glioma-bearing mice preferentially accumulated
in the brain tumors, suggesting their tumor-targeting ability.
In addition, the MRI results demonstrated substantial signal
enhancement in mice treated with CTX-modified contrast agent,
which reached a maximum level at 5min for both gliomas and
liver tumors (Huang et al., 2011).
Olson et al. developed a G5 PAMAM dendrimer coated with
activatable cell-penetrating peptides (ACPPs) bearing Cy5 or Gd
or both for the dual monitoring of matrix metalloproteinase
(MMP) activity. The uptake of ACPP-conjugated nanoparticles
in a human fibrosarcoma cell line was 4- to fifteen-fold higher
than that of bare nanoparticles. Residual tumors and metastases
as small as 200μm were successfully detected using OI. In the
presence of protease, Gd-labeled nanoparticles released high lev-
els of Gd (30–50μm) to the tumor parenchyma, which resulted
in enhanced monitoring using T1-weighted contrast for a longer
period after injection (Olson et al., 2010).
Inadequacies in the ability to image and treat malignant
gliomas are mainly due to the blood-brain barrier. Sarin et al.
developed several Gd-DTPA-functionalized PAMAM dendrimers
of various sizes for transvascular delivery across the blood-
brain barrier. When administered intravenously in RG-2 glioma-
bearing mice, Gd- and fluorescent dye-functionalized dendrimers
(11.7–11.9 nm) effectively crossed the blood-brain barrier and
accumulated in the tumors. In this study, the authors found that
the physiological upper limit of nanoparticle size for travers-
ing the blood-brain barrier was less than 11.7–11.9 nm (Sarin
et al., 2008). This investigation also showed that in the physi-
ological state, a fibrous glycocalyx covers the luminal surface of
the blood-tumor barrier (BTB) of both the brain tumor and the
peripheral tumor microvasculature, which is the major impedi-
ment for the transport of particles. Hence, the authors indicated
that the peripheral tumor vasculature is highly permeable to
macromolecules smaller than approximately 12 nm due to the
presence of a greater number of pores underlying the glycocalyx
of the BTB (Huang et al., 2011). Nanoglobular Gd-DOTA conju-
gates [lysine dendrimers (G2 and G3) with cubic silsesquioxane
cores] were attached to the peptide CLTI, which specifically binds
to fibrin-fibronectin complexes that are present in the tumor
extracellular matrix (Pilch et al., 2006), and were subsequently
used for MRI identification of tumor tissues in female nude
mice bearing MDA-MB-231 human breast carcinoma xenografts.
The T1 relaxivities of the targeted G2 and G3 nanoglobules
were 7.92 and 8.20mM−1s−1, respectively, and the nanoglobules
exhibited greater contrast enhancement in tumor models than
corresponding non-targeted contrast agents (Tan et al., 2014). In
another study, a Gd-DTPA-PAMAM-PEG dendrimer was con-
jugated to T7, a peptide that has an affinity for Tf receptors
expressed on gliomas and liver cancer cells (Han et al., 2010,
2011a). T7-conjugated Gd-DTPA-PAMAM-PEG dendrimers
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(T7- GdDTPA-PAMAM-PEG) were then used for MRI identi-
fication of tumors in human hepatocarcinoma Bel-7402- and
glioma C6-bearing mice. T7-GdDTPA-PAMAM-PEG exhibited
an excellent ability to target tumors in hepatocarcinoma-bearing
mice; moreover, the accumulation of T7-GdDTPA-PAMAM-PEG
was 162.5% times that of PAMAM-PEG. However, the pep-
tide conjugate was insensitive to gliomas (Han et al., 2011b).
Multifunctional nanoparticles carrying Gd-DTA and FA conju-
gated to cross-linked G5 PAMAM dendrimers (dendrimer nan-
oclusters) were developed for tumor-targeted MRI. FITC-labeled
dendrimer nanoclusters were readily taken up by folate receptor-
expressing KB cancer cells, and in the presence of free FA, cell
uptake was significantly reduced, suggesting receptor-mediated
uptake. In mice bearing KB xenograft tumors, subcutaneously
administered dendrimer nanoclusters gradually accumulated in
the tumors; this accumulation was detected with a strong MRI
signal. The incorporation of FA in the dendrimer nanoclusters
established tumor specificity, which resulted in enhanced images
(Cheng et al., 2010).
OI
OI is a non-invasive technique that can be broadly divided into
fluorescence and bioluminescence imaging. Fluorescence imaging
is based in principle on using external light energy of an appro-
priate wavelength to excite a fluorophore; the excited fluorophore
then emits a light of longer wavelength with lower energy. In
contrast, bioluminescence imaging involves a chemical reaction
between target and substrate molecules to generate luminescence,
which is detected externally as evidence of a molecular process
(Luker and Luker, 2008; Weissleder and Pittet, 2008; Willmann
et al., 2008). The main challenges to OI are limited tissue pene-
tration and tissue autofluorescence. Light in the visible spectrum
is strongly absorbed by hemoglobin and other biomolecules, such
as water and lipids, which significantly reduces the signal by
ten-fold. As an alternative to light in the visible region of the spec-
trum, light in the near infrared (NIR) region (600–1000 nm) has
been used to image fluorescence in deeper tissues because tissue
autofluorescence is reduced significantly in the NIR region, and
little absorption of light by the endogenous biomolecules occurs.
Hence, tremendous effort has been invested in the development
of NIR probes for OI.
QUANTUM DOTS
Semiconducting fluorescent nanocrystals known as quantumdots
(QDs) have been widely used as probes for biomedical imaging
and labeling due to their unique optical properties. QDs exhibit
broad absorption spectra, high quantum yields, low photobleach-
ing, and resistance to chemical degradation compared to tradi-
tional fluorophores, such as organic dyes (Bruchez et al., 1998;
Medintz et al., 2005; Michalet et al., 2005). For cancer-related
molecular and cellular imaging applications, the surface of QDs is
usually modified with biomolecules, such as antibodies, peptides
or small molecules that have the ability to adhere and respond to
receptors or antigens present on target cells (Zhang et al., 2008;
Lee et al., 2010a; McCarthy et al., 2010; Cheng and Cheng, 2012;
Pericleous et al., 2012). Substantial developments in nanotech-
nology and materials chemistry have encouraged scientists to
engineer QDs to carry therapeutic agents for concurrent imaging
and therapy.
Epidermal growth factor receptor (EGFR) is a transmem-
brane glycoprotein that is overexpressed in breast cancers and
can be utilized as a biomarker for imaging (Herbst, 2004). Yang
et al. developed anti-EGFR antibody-conjugated QDs for targeted
breast cancer imaging. Initially, carboxylic acid-functionalized
QDs were covalently linked to the primary amine of modi-
fied nickel (II) nitrilotriacetic acid (NNTA) via a stable amide
bond. To target EGFR, a histidine-tagged anti-EGFR antibody
(ScFv EGFR) was conjugated to the NNTA-QDs. In vitro stud-
ies clearly demonstrated that the targeted NNTA-QDs exhibited
an affinity for EGFR-overexpressing breast cancer cells (4T1
and MDA-MB-231) and were readily internalized, whereas non-
targeted NNTA-QDs showed no significant binding to breast
cancer cells (Yang et al., 2009b). Gao et al. reported prostate-
specific membrane antigen (PSMA)-bearing QD conjugates for
targeted in vivo imaging of prostate cancer. Initially, QDs were
sequentially coated with n-octylphosphine oxide and a carboxylic
acid-bearing amphiphilic polymer. The polymer served to protect
the QDs from enzymatic digestion and hydrolysis in vivo. Surface-
coated QDs were then conjugated to PEG to prolong their circu-
lation time in vivo. In vitro studies demonstrated that the targeted
QDs were readily taken up by PSMA-overexpressing C4-2 human
prostate cancer cells, while non-targeted PEGylated QDs exhib-
ited minimal uptake by prostate cancer cells. When administered
to prostate tumor-bearing nude mice, targeted QDs accumulated
in the tumors with high specificity and exhibited a strong flu-
orescence signal, whereas no significant fluorescence signal was
observed in mice injected with PEGylated QDs. Further studies,
including biodistribution and histological analyses, clearly illus-
trated the prostate tumor-targeting potential of functionalized
QDs (Gao et al., 2004). Bagalkot et al. developed QD-Apt, QDs
functionalized with A10 RNA aptamer that recognizes the extra-
cellular domain of PSMA for prostate cancer imaging, therapy
and sensing. Doxorubicin (DOX) was able to bind to the double-
stranded A10 RNA aptamer via non-covalent interactions, and
the resulting conjugate (QD-Apt DOX) gained reversible self-
quenching properties based on bi-fluorescence resonance energy
transfer (Bi-FRET); in this process, QD-DOX and QD-Apt DOX
acted as donor-acceptor pairs (Figure 4). Thus, the fluorescence
of the QD-Apt DOX conjugate was quenched when intact, and
the release of DOX from QD-Apt DOX inside of the cell allowed
the nanoparticles to recover their fluorescence. When incubated
with PSMA-overexpressing cancer cells (LNCaP), the nanoparti-
cles were taken up and delivered DOX, which was confirmed by a
strong fluorescence signal (Bagalkot et al., 2007).
Scroeder et al. developed lipodots, which consisted of QDs
entrapped in a lipid shell and post-loaded with a folate-lipid con-
jugate for targeting tumors. In vitro confocal observations showed
that the targeted lipodots were readily taken up by folate receptor-
overexpressing cancer cells (J6456-FR and KB-FR), confirmed by
a strong fluorescence signal, while non-targeted lipodots were
found to be insensitive. In vivo studies with mice bearing J6456-
FR tumors demonstrated the tumor-targeting ability of targeted
lipodots following intra-peritoneal injection (Schroeder et al.,
2007). Mulder et al. developed targeted bimodal nanoparticles
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FIGURE 4 | (A) A schematic illustration of QD-Apt(Dox) Bi-FRET. Confocal
laser scanning microscopy images of QD-Apt DOX conjugates incubated in
PSMA-expressing LNCaP cells at (B) 0h and (C) 1.5 h. DOX and QDs are
shown in red and green, respectively, and the lower right images in each
panel represent an overlay of DOX and QD fluorescence (Bagalkot et al.,
2007), © 2007, American Chemical Society.
(pQDs) that consisted of magnetically detectable PEGylated
lipids that were covalently coupled to QDs bearing RGD (spe-
cific for αvβ3 integrin interaction). When incubated with αvβ3
integrin-overexpressing human umbilical vein endothelial cells
(HUVECs), enhanced uptake of pQDs by HUVECs was observed
compared to that of non-targeted pQDs. The optical properties of
the pQDs were preserved, and they exhibited very high r1 relax-
ivity. The overall results suggested the ability of the nanoagent
to target tumor vasculature (Mulder et al., 2005). In a simi-
lar study, Cai et al. evaluated the tumor vasculature-targeting
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FIGURE 5 | (A) RGD-bearing QD705 conjugates and (B) in vivo fluorescence imaging of tumor vasculature in a U87MG tumor-bearing mouse at various time
intervals (Cai et al., 2006), © 2006, American Chemical Society.
ability of RGD-coupled QD 705 (QD705-RGD) (Figure 5). When
administered intravenously in athymic nude mice bearing sub-
cutaneous U87MG human glioblastoma tumors, QD705-RGD
exhibited a significant ability to target tumor vasculature, and
the tumor fluorescence intensity reached a maximum at 6 h post-
injection. However, non-specific accumulation was also observed
in the lymph nodes, liver, and bone marrow (Cai et al., 2006).
Chang et al. prepared protease-activatable QDs that consisted of
gold nanoparticles bound to QDs via a peptide sequence sus-
ceptible to degradation by enzyme proteases. When intact, the
conjugate was optically quenched with a 71% reduction in lumi-
nescence; however, the conjugate became highly luminescent after
the peptide linker was degraded by proteases. This type of probe
could be useful for monitoring the biological activities of pro-
teases (Chang et al., 2005). Smith et al. observed and recorded
the binding of RGD-conjugated QD800 (QD with emission at
approximately 800 nm) to tumor blood vessels expressing αvβ3
in mice models. RGD-QD800 demonstrated significant uptake
by tumors compared to control QDs (PEG-QD800 and RAD-
QD800), suggesting the ability of RGD-QD800 to target tumors
overexpressing αvβ3. Intra-vitalmicroscopy observations in mice
bearing an SKOV-3 ear tumor clearly showed that the targeted
QDs did not target tumor cells but did target the tumor neovas-
culature. This observation was presumably due to their relatively
large size (∼20 nm in hydrodynamic diameter), which prevented
the nanoparticles from extravasating into the tumor. The authors
also found that RGD-QD800 adhered to their targets as aggre-
gates rather than as individual nanoparticles (Smith et al., 2008).
In an interesting work by Akerman et al., QDs were conjugated
to three different peptides (GFE, F3, and Lyp-1) to demon-
strate their specific targeting abilities. In vivo studies showed that
QD-GFE (lung-targeting) conjugates accumulated in the lungs
of mice following intravenous administration, whereas QD-F3
and QD-Lyp-1 conjugates specifically targeted blood vessels or
lymphatic vessels in tumors. Unfortunately, the QDs were not
sufficiently stable to remain luminescent in living cells and tis-
sues. Hence, the QDs used in this investigation are not feasible
for in vivo applications (Åkerman et al., 2002). In addition to
RGD functionalization, QDs have been conjugated to several
other peptides for tumor-specific targeting. Gao et al. designed
and chemically synthesized anti-HER2 affibody molecules (Z
HER2:342) for the specific targeting of HER2-expressing cells and
tumors in imaging. Affibodies are small protein molecules that
are engineered to specifically bind targets, such as other pro-
teins or peptides. The synthesized Z HER2:342-QD conjugates
exhibited tumor-targeting ability with superior imaging contrast
in mice bearing HER2-overexpressing SKOV3 tumors compared
to low-level HER2-expressing PC-3 mice. These results indi-
cated that the Z HER2:342-QD conjugates were target-specific
and had the potential to image HER2-overexpressing cells (Gao
et al., 2011). Diagaradjane et al. prepared EGF-conjugated QDs
that had the ability to distinguish EGF receptor-overexpressing
tumors from nearby normal tissues. In vivo imaging exhib-
ited three distinct phases for the EGF-QD nanoprobes: tumor
influx (∼3min), clearance (∼60min) and accumulation (1–6 h).
The prepared EGF-QDs exhibited optimal pharmacokinetics
and superior docking ability to EGFR, which allowed quantifi-
able imaging of EGFR expression in human colorectal cancer
xenografts in mice (Diagaradjane et al., 2008).
Qian et al. employed Tf and anti-claudin 4-conjugated
CdSe/CdS/ZnS QDs for targeted imaging of pancreatic can-
cer. The targeted optical agent was stable and had superior
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photoluminescence efficiency, demonstrating pancreatic cell-
specific uptake using a monoclonal antibody for anti-claudin 4.
The targeting agent used in this study can be further tuned to
image pancreatic cancer in its early stages (Qian et al., 2007).
Yong et al. used anti-claudin 4- and anti-prostate stem cell
antigen-bearing non-cadmium-based QDs (InP/ZnS QDs) as
highly efficient, non-toxic targeted optical probes for imaging live
pancreatic cancer cells. Antibodies, such as anti-claudin 4 and
anti-prostate stem cell antigen, whose receptors are known to be
upregulated in both primary and metastatic pancreatic cancers,
were used as targeting agents. The targeted QDs demonstrated
affinity and specific targeting for pancreatic cancer cell lines in
vitro. In addition, the receptor-mediated delivery of targeted QDs
was further confirmed by the observation of poor in vitro target-
ing in non-pancreatic cancer cell lines, which were negative for the
claudin-4-receptor. These observations suggest that InP/ZnS QDs
could be used as an efficient OI imaging nanoprobe in diagnos-
tic imaging, particularly for early detection of pancreatic cancer
(Yong et al., 2009).
Clearance of QDs
Choi et al. established the effect of hydrodynamic diameter
(HD) and surface charge of QDs on their renal clearance. QDs
with HD smaller than 5.5 nm demonstrated rapid and effi-
cient urinary excretion. With the increase of HD from 4.36 to
8.65 nm, the serum half-life increased from 48min to 20 h (25
fold increase), suggesting a positive correlation between serum
half-life and HD. QDs with HD range of 4.36–5.52 was cleared
form the body through renal mechanism, while QDs with large
HD did not undergo renal clearance and was confined to the
liver, lung and spleen. The anionic or cationic surface charge
of QDs increased the HD by 15 nm due to the charge related
adsorption by serum proteins, which decreased the renal clear-
ance consequently. Whereas, zwitterionic coatings prevented the
serum protein adsorption and demonstrated increased solubility
and improved renal filtration (Choi et al., 2007).
Fischer et al. investigated the clearance of two differ-
ent QD conjugates [mercaptoundecanoic acid (QD-LM) and
bovine serum albumin (QD-BSA)] administered intravenously
in rats. QD-BSA exhibited accelerated clearance (1.23 ±
0.22mLmin−1kg−1) from the blood, which resulted in higher lev-
els of liver uptake (99%) compared to QD-LM (40%). However,
both conjugates were not detected in urine or feces during the
entire time of experiment (10 days). This may be presumably due
to large HD (25 nm for QD-LM and 80 nm for QD-BSA) (Fischer
et al., 2006). Schipper et al. studied the clearance of two com-
mercially available QDs with sizes 12 and 21 nm in diameter and
effect of PEGylation on their clearance. The results showed that a
2000mW PEG coating prolonged the blood half-life, but delayed
accumulation in the liver. All particles were rapidly taken up and
accumulated in the liver, whereas PEGylated particles accumu-
lated in the bone, while unPEGylated particles did not (Schipper
et al., 2007).
GOLD NANOPARTICLES
The popularity of gold nanoparticles (AuNPs) in biomedical
applications has increased significantly in recent years owing to
their unique size-dependent properties. AuNPs are highly bio-
compatible, easy to prepare and generally regarded as non-toxic
(Boisselier and Astruc, 2009). Their characteristic surface plas-
mon absorption property is responsible for their excellent optical
properties, making them attractive candidates for labeling and
imaging. Tailor-made AuNPs of different sizes, shapes and func-
tionalized with various targeting molecules have been used for
a number of applications in cancer therapy and imaging (Tong
et al., 2009; Kumar et al., 2013). Due to their vast potential, several
AuNP-based formulations are currently undergoing phase I and
phase II clinical trials for cancer treatment (Thakor et al., 2011).
The ability of AuNPs to quench fluorophores in close prox-
imity encouraged Lee et al. to develop protease-sensitive NIRF
probes for in vivo cancer imaging. In this study, AuNPs (20 nm)
were stabilized by a Cy5.5-labeled MMP substrate, and the flu-
orescence of Cy5.5 was strongly quenched by the coordinated
dye-dye and AuNP-surface quenching effects. When incubated
with MMP in vitro, cleavage of the substrate allowed the probe
to recover a strong fluorescence signal. In MMP-2-positive, SCC-
7 tumor-bearing mice, the administered probes demonstrated
preferential tumor accumulation with a strong fluorescence sig-
nal (Lee et al., 2008). Popovtzer et al. developed gold nanorods
(AuNRs) conjugated to UMA9 antibodies for the targeted CT
imaging of head and neck cancers. SCC represents more than
90% of all head and neck cancers, and UMA9 antibody can target
SCC tumors in vivo. In vitro CT imaging revealed that targeted
AuNRs were readily taken up by A9 antigen-overexpressing can-
cer cells (UM-SCC-1 and UM-SCC-5), which showed strongly
selective X-ray attenuation that was distinct from that of normal
cells (Popovtzer et al., 2008). Mu et al. developed AuNP-based
activatable NIR probes functionalized with PEG and heteroge-
neous monolayers of dye-labeled peptides to monitor proteolytic
activity in vivo. In this study, AuNPs (20 nm in diameter) were
modified with a heterogeneous monolayer of fluorophore (Q670)
and dark quencher (BHQ-2)-labeled peptide substrates that were
responsive to proteases, such as trypsin and uPA (Figure 6). The
resulting system demonstrated strong quenching properties due
to the close proximity between Q670 and BHQ-2 to the AuNPs. In
the presence of target enzymes in vitro, the nanoprobes recovered
fluorescence with a five- to eight-fold increase in signal. In addi-
tion, AuNP-based probes exhibited prolonged circulation time in
vivo with a t1/2 of more than 4 h and high image contrast in a
mouse tumor model (Mu et al., 2010).
Chanda et al. developed bombesin (BBN) peptide-conjugated
AuNPs to target gastrin-releasing peptide (GRP) receptors that
are overexpressed on prostate cancer cells. BBN peptides exhibit a
high affinity for GRP receptors that are overexpressed in prostate,
breast and small-cell lung carcinomas in vivo. In vitro radioio-
dinated BBN displacement assays clearly demonstrated the GRP
receptor specificity and binding affinity of the AuNP–BBN con-
jugates in PC-3 cells. In vivo CT imaging in prostate tumor-
bearing, severe combined immune deficiency mice showed that
intra-peritoneally administered AuNP–BBN conjugates preferen-
tially accumulated in the tumors with little or no uptake in the
liver relative to controls (Chanda et al., 2010). Kim et al. used
multifunctional aptamer-AuNP conjugates for the combined tar-
geted CT imaging of and therapy for prostate cancer. AuNPs
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FIGURE 6 | Schematic diagrams of (A) AuNP probe synthesis and
activation, and (B) in vivo near-infrared fluorescence imaging of
subcutaneous tumor phantom models consisting of PuraMatrix
peptide hydrogel mixed with AuNP probe in the presence or absence
of trypsin as compared to unlabeled AuNPs (Mu et al., 2010), © 2010,
American chemical society.
were coated with thiol-functionalized capture oligonucleotides
(ONT) that consisted of an A10 spacer and a (TCG)7ONT,
which was hybridized with PSMA aptamer-(CGA)7 to create a
double-stranded GC region on which several DOX molecules
could be loaded. The targeted PSMA aptamer-AuNPs exhibited
more than four-fold greater CT intensity in LNCaP cells that
overexpressed PSMA antigen than in PSMA-negative PC3 cells.
In addition, drug-loaded, aptamer-AuNPs demonstrated target-
specific drug delivery to target cancer cells but not non-targeted
cells (Kim et al., 2010). Chen et al. developed FA-conjugated
bimodal G5 dendrimer nanoparticles carrying AuNPs loaded
with Gd for targeted dual CT/MR tumor imaging. Themultifunc-
tional nanoprobes demonstrated the ability to image FA receptor
overexpressing cancer models in vitro and in vivo (Chen et al.,
2013).
Sun et al. reported tumor-targeting probes based on AuNPs
for dual CT/OI of cancer. The targeted probe consisted of a
Cy5.5-labeled, MMP-activatable peptide substrate that was chem-
ically conjugated to glycol chitosan-coated AuNPs. The fluo-
rescence of Cy5.5 was strongly quenched by BHQ3. However,
when exposed to MMP-2, the quenched fluorescence was recov-
ered by peptide cleavage. Following intravenous injection of
the targeted AuNPs in mice bearing MMP-2-positive, HT-29
tumors, the targeted nanoparticles selectively accumulated in
tumors, as observed by CT/fluorescence imaging (Sun et al.,
2011). Deng et al. developed molecular beacons based on rod-
shaped AuNPs for the targeted in vivo detection of matriptase
expression on tumors. The molecular beacons consisted of an
activatable fluorophore-peptide conjugate attached to AuNPs.
The quenched fluorescence of the fluorophore by the AuNPs was
restored when exposed to matriptase. After intratumoral injec-
tion of the targeted AuNPs in nude mice bearing HT-29 tumor
xenografts with high matriptase expression, a strong fluorescence
signal was observed in the tumors after 8 h, clearly indicating
the tumor-targeting ability of the AuNPs (Deng et al., 2013).
Multifunctional nanoparticles based on AuNRs were developed
for targeted positron emission tomography (PET) imaging of
and therapy for cancer. The multifunctional nanoparticle system
consisted of PEGylated AuNRs; cyclic RGD and a 64Cu-chelator
were attached to the distal ends of PEG, and DOX was conju-
gated to the AuNRs via a linker that was vulnerable to tumor
acidity. The AuNRs demonstrated target specificity in a rele-
vant model both in vitro and in vivo. However, in U87MG
tumor-bearing mice, PET imaging revealed similar biodistri-
bution of both targeted and non-targeted AuNRs (Xiao et al.,
2012). Lee et al. used heparinase-specific targeted AuNPs (AuNP-
HHep)-based activatable probes to detect and induce apoptosis
in metastatic cancer cells. AuNP-HHep consisted of AuNPs con-
jugated to fluorophore-labeled heparin and RGD-bearing PEG.
The fluorescence was quenched by the surface of the AuNPs and
was recovered after exposure to the enzyme heparinase, which is
known to be overexpressed in metastatic cancer cells. In addi-
tion, this targeted probe demonstrated highly specific apoptotic
activity for cancer cells over-expressing αvβ3 on their membranes,
revealing that the accumulation of heparin within the cells trig-
gered apoptotic events. The probe employed in this study could
be useful for both imaging and treatment of metastatic cancers
(Lee et al., 2010b).
Clearance of AuNPs
AuNPs can be excreted by kidney or liver, however, substan-
tial research efforts are needed to determine the factors that
affect mode of excretion. Balasubramanian et al. investigated the
biodistribution of AuNPs and found that 20 nm particles accu-
mulated in the kidneys starting at 1 month with a decrease in
Au levels in urine. It was explained that AuNPs may adsorb to
the serum proteins or aggregate over time, which increased the
particle size making them difficult to pass through glomeru-
lar membrane. Authors suggested that prolonged accumulation
of AuNPs in the kidneys could damage the glomerular mem-
brane and reduce the excretion (Balasubramanian et al., 2010).
Zhang et al. investigated the biodistribution of two PEGylated
AuNPs with sizes 20 and 80 nm in diameter. Authors found
that size of NPs strongly influence the biodistribution. For
instance, 20 nm AuNPs demonstrated prolonged blood circu-
lation and reduced uptake by the liver and the spleen com-
pared to 80-nm AuNPs. Importantly, 20-nm AuNPs also excreted
from the body, suggesting the validity of AuNPs with size less
than 20 nm in diameter for in vivo applications (Zhang et al.,
2009).
In their work, Lipka et al. showed that PEG (10 kDa) modi-
fied AuNPs with a HD of 31 nm showed the most clearance via
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the hepato-biliary pathway compared to PEG (750Da) modi-
fied AuNPs with a HD of 21 nm. In this study, AuNPs with PEG
(10 kDa) are the NPs with the greatest diameter and a study by
Johnston et al. (2010) showed that 1.4 nm NPs exhibited higher
hepato-biliary clearance compared to 18 nm. From these results,
authors suggested that bile excretion may be significantly depen-
dent on particles PEGylation but not on their size (Lipka et al.,
2010).
POLYMERIC NANOPARTICLES
In addition to metallic nanoparticles, the use of polymeric
nanoparticles (PN) as imaging probes have received significant
attention due to their unique properties. PN-based imaging
probes have several advantages over conventional low-molecular-
weight probes, including prolonged circulation time, improved
stability, and target specificity, passivity to the immune system
and little or no toxicity. In recent years, biological science in asso-
ciation with polymer science has yielded novel hybrid materials
with sophisticated architectures for clinical imaging and ther-
apy (Duncan, 2003; Mitra et al., 2005; Lee et al., 2010a; Park,
2012).
Scherer et al. developed NIR polymer-based proteolytic bea-
cons (PB-M7NIR) for the in vivo detection and quantitation
of MMP-7 activity. PB-M7NIR was a PEGylated PAMAM-G4
dendrimer that was covalently coupled to a Cy5.5-labeled pep-
tide substrate [Cy5.5-ahx-RPLALWRS(ahx)C] that monitored
MMP-7 activity and to a quencher (AF750). In vitro OI stud-
ies showed a five-fold increase in fluorescence. The intravenous
administration of PB-M7NIR in mice allowed for selective tumor
visualization and localization with two point two-fold improved
signals in MMP7 SW480 tumors relative to MMP7-negative
tumors (Scherer et al., 2008). Oslon et al. developed activat-
able cell-penetrating peptide (ACCP)-conjugated bimodal G5
PAMAM dendrimer nanoparticles (ACCPDs) labeled with Cy5,
Gd, or both. Cellular uptake of these nanoparticles in tumors
was four to fifteen-fold higher than that of bare ACPPs. With
OI, residual tumors and metastases as small as 200μm were
detected. ACCPDs were also used to visualize tumors during
surgery (Olson et al., 2009). Successful surgical removal of tumors
depends on the surgeon’s ability to recognize and differentiate
tumors from normal tissues; thus, it would be beneficial to objec-
tively assess tumor margins while performing surgery. ACCPDs
demonstrated superior ability to identify tumor tissue in tumor-
bearing mice during surgery relative to ACCPs. As a result, fewer
residual cancer cells were left in the animals following surgery, and
the animals showed prolonged tumor-free survival and overall
survival relative to animals resected using traditional bright-field
illumination (Nguyen et al., 2010). In another study, Galande
et al. developed self-quenched, dendrimeric peptide-based probes
using multiple antigenic peptide (MAP), which fluoresced only
after enzymatic treatment. The peptide-based probe was devel-
oped on a solid support that consisted of a dipeptide cathepsin
S substrate (Leu-Arg) and PEG chains on the dendritic arms. An
NIR dye, CyTE777, was attached to the N-terminus of the pep-
tide to establish a dye-dye self-quenching system. In vitro studies
showed that in the presence of protease cathepsin S, the peptide-
based probe demonstrated a more than seventy-fold increase in
FIGURE 7 | (A) MMP-sensitive NS and (B) in vivo NIR fluorescence
tomographic images of subcutaneous SCC7 tumor-bearing mice after
intravenous injection of the NS (Lee et al., 2009), © 2009, American
Chemical Society.
and more than 95% recovery of fluorescence emission (Galande
et al., 2006).
Lee et al. developed a self-assembled, chitosan nanoparticle-
based nanosensor (NS) that consisted of activatable MMP-
specific NIR fluorogenic peptides with an NIR dark quencher
BHQ-3 (Figure 7). This type of peptide substrate-mediated
fluorescence labeling of nanoparticles could be strongly dual-
quenched by both the dye-dark quencher and the NIR dye-dye
self-quenching mechanisms. In the presence of MMP, the NIR-
dye substrate was cleaved, which resulted in NIR fluorescence
signal recovery. Intravenously administered NSs demonstrated
enzyme specificity in both MMP-positive, SCC-7 xenograft
tumor and colon cancer mouse models (Lee et al., 2009). Kim
et al. developed a polymeric nanoparticle-based probe that
could sense early apoptosis. The probe was an on/off system
that consisted of a caspase-3 cleavable, NIR dye peptide sub-
strate (Cy5.5-DEVDC) covalently attached to a deoxycholic acid-
bearing polyethyleneamine conjugate. Due to the close proximity
of Cy5.5 dyes to the nanoparticle surface, the fluorescence was
self-quenched (off state). In the presence of caspase-3 enzyme
in vitro, the nanoparticle recovered fluorescence (a ten-fold
increase) that allowed monitoring of caspase-dependent apopto-
sis induced by tumor necrosis factor apoptosis inducing ligand in
living HeLa cells (Kim et al., 2006).
CLEARANCE OF PN
Gref et al. studied the effect of PEG chain length (2 and
5 kDa) in preventing plasma protein adsorption on the sur-
face of poly(lactic acid)-PEG (PLA-PEG) NPs. PLA-PEG (5 kDa)
demonstrated minimal protein adsorption (∼80%) compared
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Table 1 | Advantages and disadvantages of imaging modalities used with targeted or non-targeted imaging agents.
Modality Advantages Disadvantages Contrast agents Radiation
CT Unlimited tissue depth penetration
High spatial resolution
Can be used for whole body imaging
Low acquisition time
Anatomical imaging
Radiation exposure
Poor soft tissue contrast
Krypton
Xenon
Iodine
Barium
X-rays
Positron
emission
tomography
(PET)
Unlimited tissue depth penetration
Can be used for whole body imaging
Detailed anatomical information can be obtained
when combined with CT or MRI
Radiation exposure
Low spatial resolution and
long acquisition time
Expensive
11C
18F
64Cu
High energy
γ-rays
MRI Unlimited tissue depth penetration
Non-ionizing radiation
High spatial resolution and excellent soft tissue
contrast
Whole body imaging possible
Expensive
Long acquisition time and
limited sensitivity
Gd 3+
SPIO, USPIO
Radio waves
Ultrasound High spatial resolution
Real time imaging with low acquisition time
Highly sensitive and inexpensive
Cannot be used for whole
body imaging
Microbubbles High frequency
sound
OI High spatial resolution
Real time imaging with low acquisition time
Highly sensitive and inexpensive
Cannot be used for whole
body imaging
limited tissue depth
penetration
Fluorescent dyes
and molecules
Light sensitive NPs
Visible or
near-infrared
light
to non-PEGylated PLA NPs. PEG content between 2 and 5%
was determined as a threshold value for optimal protein resis-
tance. Interestingly, distances of 1–2 nm between two terminally
attached PEG chains were estimated for minimal protein adsorp-
tion (Gref et al., 2000). Using polystyrene NPs of two sizes 50
and 500 nm, Kimura et al. studied the relation between protein
adsorption kinetics and their liver uptake. 50 nm NPs exhibited
rapid hepatic uptake when incubated with serum before transfu-
sion in the rat liver. In vivo biodistribution of particle sizes of 50
and 500 nm revealed significant levels of agglomeration of larger
particles in the liver. The surface charge of NPs has profound
effect on uptake by the phagocytic system. Positively charged NPs
are expected to have high non-specific internalization rate and
short half-life compared to neutral or negatively charged NPs
(Nagayama et al., 2007).
Kataoka et al. investigated the biodistribution of tyrosine (tyr)
and tyrosine-glutamic acid (tyr-glu) conjugated PEG-poly (D,L-
lactide) micelles in mice. Both of these micelles [tyr (neutral) and
tyr-glu (negative)] showed a significant long circulation time in
the blood compartment with 25% of injected dose still circulating
even at 24 h. Biodistribution studies revealed that anionic micelle
exhibited lower uptake into the liver and spleen compared to a
neutral tyr-conjugated micelle, suggesting a substantial role of the
anionic charge in avoiding non-specific organ uptake (Yamamoto
et al., 2001).
CONCLUSION AND PERSPECTIVES
The current medical imaging technologies used in the clinic for
cancer diagnosis and staging depend on anatomical changes.
The advent of MI allows expression identification of specific
biomolecules based on functional changes that are correlated with
the genesis of cancer, which greatly enhances our understand-
ing of disease mechanisms and progression. In addition, critical
data obtained fromMI would enable clinicians to plan and design
treatments, which is crucial for patient compliance and survival.
The development of targeted probes and optimizing their ability
to reach a site of interest remains a herculean task. The inabil-
ity of probes to cross various biological barriers largely accounts
for their shortcomings. An ideal probe should essentially pos-
sess a high level of specificity for a target and should successfully
overcome biological barriers.
Substantial developments in nanotechnology have resulted in
the development of imaging probes functionalized with a diverse
range of ligands. Due to the versatile nature of nanoparticles,
creating custom-made probes with unique properties, such as
superior targeting ability and enhanced in vivo half-life, is possi-
ble. Owing to these features, several multimodal imaging systems
have been developed as powerful tools for accurate cancer diag-
nosis because they integrate more than one imaging technique.
For instance, an MI probe that included NIR dye and MR con-
trast agents was developed and subsequently used for preoper-
ative MRI and intraoperative brain tumor delineation through
OI. Although nanoparticles have shown promising results as
MI probes, proper safety evaluation regarding their toxicity is
absolutely necessary before they enter clinical use.
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